Forecast

The analysts' average price target is +15,79€ (+105,87%). The median is +14,59€ (+90,22%).

Buy	11
Hold	2
Sell	0

News Go to news feed

Evolus beats Q2 2026 revenue forecast and raises full-year target

Evolus reported Q2 2026 revenue of $84.1m (+21% y/y), beating analysts' estimates and raising the lower end of its full-year revenue guidance to $330m. Adjusted EBITDA was positive at $4.7m for the third consecutive quarter, although EPS of -$0.12 was more negative than expected. Management emphasized portfolio diversification through Evolysse and Profhilo and additional product launches; the stock rose about 5.7% in after-hours trading. » More on de.investing.com
Evolus enters exclusive license and distribution agreement for Profhilo in the US

Evolus has reached an exclusive license and distribution agreement with Swiss pharmaceutical company IBSA for the skin injection Profhilo in the US. Evolus will assume the development activities required for US approval and will market the product after approval; the agreement includes no upfront payments and is based on a transfer-pricing model. The company expects no impact from the agreement on its 2026 guidance or on the revenue and profitability targets for 2028. Profhilo, a superficially acting hyaluronic acid formulation to improve skin quality, has already been used in millions of treatments worldwide since 2015 and complements Evolus' existing portfolio such as Jeuveau and Evolysse. » More on de.investing.com
Evolus: shareholders reelect Brady Stewart and Vikram Malik and approve executive compensation

At Evolus' annual general meeting, Brady Stewart and Vikram Malik were reelected as Class II directors for three years. Shareholders confirmed Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and voted in a non-binding advisory vote to approve the compensation of the named executive officers. Additionally, the company reported mixed Q1 results (EPS missed, revenue slightly above expectations) and plans the European launch of the Estyme dermal filler line. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Evolus has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Evolus had revenue of 73.68m€ and net profit of −7.06m€

(EUR)	Jun 2026	YoY
Revenue	+73.68m	25,15%
Gross profit	+50.10m	30,30%
Net profit	−7.06m	51,49%
EBITDA	−3.53m	46,83%

Fundamentals

Metric	Value
Market capitalization	+510.24m€
Number of shares	65.85m
52-week high/low	+7,83€ - +3,31€
Dividends	No
Beta	1,36
P/E ratio	−17,43
PEG ratio	−0,25
P/B ratio	−19,26
P/S ratio	+1,88

Company profile

Evolus, Inc. ist ein leistungsfähiges Schönheitsunternehmen, das medizinisch-ästhetische Produkte für Ärzte und ihre Patienten in den Vereinigten Staaten anbietet. Es bietet Jeuveau an, eine firmeneigene 900-Kilodalton-Formulierung von gereinigtem Botulinumtoxin Typ A zur vorübergehenden Verbesserung des Aussehens von mittleren bis schweren Glabellafalten bei Erwachsenen. Das Unternehmen wurde im Jahr 2012 gegründet und hat seinen Hauptsitz in Newport Beach, Kalifornien.